Profiling the Antibody Immune Response against Blood Stage Malaria Vaccine Candidates

Clinical Chemistry - Tập 53 Số 7 - Trang 1244-1253 - 2007
Julian Gray1, Patrick Corran2,3, Elena Mangia4, Michael W. Gaunt2, Qiuxiang Li1, Kevin K. A. Tetteh2, Spencer D. Polley2, David J. Conway2,5, Anthony A. Holder6, Tito Bacarese-Hamilton1, Eleanor M. Riley2, Andrea Crisanti1
1Faulty of Natural Sciences, Imperial College London, London, United Kingdom
2Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom
3Immunology Division, National Institute for Biological Standards and Control, South Mimms, United Kingdom
4Department of Experimental Medicine, University of Perugia, Perugia, Italy
5MRC laboratories, Fajara, Banjul, The Gambia
6National Institute for Medical Research, London, United Kingdom

Tóm tắt

Abstract Background: The complexity and diversity of the antibody immune response to the antigen repertoire of a pathogen has long been appreciated. Although it has been recognized that the detection of antibodies against multiple antigens dramatically improves the clinical sensitivity and specificity of diagnostic assays, the prognostic value of serum reactivity profiles against multiple microbial antigens in protection has not been investigated. Methods: Using malaria as a model we investigated whether antigen reactivity profiles in serum of children with different levels of clinical immunity to Plasmodium falciparum malaria correlated with protection. We developed a microarray immunoassay of 18 recombinant antigens derived from 4 leading blood-stage vaccine candidates for P. falciparum [merozoite surface protein 1 (MSP1), MSP2, MSP3, and apical membrane antigen (AMA)-1]. Associations between observed reactivity profiles and clinical status were sought using k-means clustering and phylogenetic networks. Results: The antibody immune response was unexpectedly complex, with different combinations of antigens recognized in different children. Serum reactivity to individual antigens did not correlate with immune status. By contrast, combined recognition of AMA-1 and allelic variants of MSP2 was significantly associated with protection against clinical malaria. This finding was confirmed independently by k-means clustering and phylogenetic networking. Conclusions: The analysis of reactivity profiles provides a wealth of novel information about the immune response against microbial organisms that would pass unnoticed in analysis of reactivity to antigens individually. Extension of this approach to a large fraction of the proteome may expedite the identification of correlates of protection and vaccine development against microbial diseases.

Từ khóa


Tài liệu tham khảo

Bacarese-Hamilton T, Gray J, Crisanti A. Protein microarray technology for unraveling the antibody specificity repertoire against microbial proteomes. Curr Opin Mol Ther2003;5:278-284.

Richie TL, Saul A. Progress and challenges for malaria vaccines. Nature2002;415:694-701.

Cohen S, McGregor IA, Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature1961;192:733-737.

Edozien JC, Gilles HM, Udeozo IOK. Adult and cord-blood gamma globulin and immunity to malaria in Nigerians. Lancet1962;2:951-955.

Sabchareon A, Burnouf T, Ouattara D, Attanath P, Bouharoun-Tayoun H, Chantavanich P, et al. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg1991;45:297-308.

Targett GA. Malaria vaccines 1985–2005: a full circle?. Trends Parasitol2005;21:499-503.

Riley EM, Allen SJ, Troye-Blomberg M, Bennett S, Perlmann H, Andersson G, et al. Association between immune recognition of the malaria vaccine candidate antigen Pf155/RESA and resistance to clinical disease: a prospective study in a malaria-endemic region of west Africa. Trans R Soc Trop Med Hyg1991;85:436-443.

Riley EM, Allen SJ, Wheeler JG, Blackman MJ, Bennett S, Takacs B, et al. Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malaria morbidity. Parasite Immunol1992;14:321-337.

Egan AF, Morris J, Barnish G, Allen S, Greenwood BM, Kaslow DC, et al. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. J Infect Dis1996;173:765-769.

Taylor RR, Allen SJ, Greenwood BM, Riley EM. IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. Am J Trop Med Hyg1998;58:406-413.

al-Yaman F, Genton B, Anders RF, Falk M, Triglia T, Lewis D, et al. Relationship between humoral response to Plasmodium falciparum merozoite surface antigen-2 and malaria morbidity in a highly endemic area of Papua New Guinea. Am J Trop Med Hyg1994;51:593-602.

Cavanagh DR, Dodoo D, Hviid L, Kurtzhals JA, Theander TG, Akanmori BD, et al. Antibodies to the N-terminal block 2 of Plasmodium falciparum merozoite surface protein 1 are associated with protection against clinical malaria. Infect Immun2004;72:6492-6502.

Okenu DM, Riley EM, Bickle QD, Agomo PU, Barbosa A, Daugherty JR, et al. Analysis of human antibodies to erythrocyte binding antigen 175 of Plasmodium falciparum. Infect Immun2000;68:5559-5566.

Struik SS, Riley EM. Does malaria suffer from lack of memory?. Immunol Rev2004;201:268-290.

Mezzasoma L, Bacarese-Hamilton T, Di Cristina M, Rossi R, Bistoni F, Crisanti A. Antigen microarrays for serodiagnosis of infectious diseases. Clin Chem2002;48:121-130.

Joos TO, Schrenk M, Hopfl P, Kroger K, Chowdhury U, Stoll D, et al. A microarray enzyme-linked immunosorbent assay for autoimmune diagnostics. Electrophoresis2000;21:2641-2650.

Bacarese-Hamilton T, Mezzasoma L, Ingham C, Ardizzoni A, Rossi R, Bistoni F, et al. Detection of allergen-specific IgE on microarrays by use of signal amplification techniques. Clin Chem2002;48:1367-1370.

Bacarese-Hamilton T, Gray J, Crisanti A. Proteome-scale analysis of the immune response against pathogenic microorganisms. Schena M eds. Protein Microarrays2005:387-400 Jones and Bartlett Sudbury, MA. .

Kimbi HK, Tetteh KK, Polley SD, Conway DJ. Cross-sectional study of specific antibodies to a polymorphic Plasmodium falciparum antigen and of parasite antigen genotypes in school children on the slope of Mount Cameroon. Trans R Soc Trop Med Hyg2004;98:284-289.

Polley SD, Tetteh KK, Cavanagh DR, Pearce RJ, Lloyd JM, Bojang KA, et al. Repeat sequences in block 2 of Plasmodium falciparum merozoite surface protein 1 are targets of antibodies associated with protection from malaria. Infect Immun2003;71:1833-1842.

Tetteh KK, Cavanagh DR, Corran P, Musonda R, McBride JS, Conway DJ. Extensive antigenic polymorphism within the repeat sequence of the Plasmodium falciparum merozoite surface protein 1 block 2 is incorporated in a minimal polyvalent immunogen. Infect Immun2005;73:5928-5935.

Burghaus PA, Holder AA. Expression of the 19-kilodalton carboxy-terminal fragment of the Plasmodium falciparum merozoite surface protein-1 in Escherichia coli as a correctly folded protein. Mol Biochem Parasitol1994;64:165-169.

Drakeley CJ, Corran PH, Coleman PG, Tongren JE, McDonald SL, Carneiro I, et al. Estimating medium- and long-term trends in malaria transmission by using serological markers of malaria exposure. Proc Natl Acad Sci U S A2005;102:5108-5113.

Saul A, Lawrence G, Smillie A, Rzepczyk CM, Reed C, Taylor D, et al. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Vaccine1999;17:3145-3159.

Hodder AN, Crewther PE, Anders RF. Specificity of the protective antibody response to apical membrane antigen 1. Infect Immun2001;69:3286-3294.

Riley EM, Morris-Jones S, Blackman MJ, Greenwood BM, Holder AA. A longitudinal study of naturally acquired cellular and humoral immune responses to a merozoite surface protein (MSP1) of Plasmodium falciparum in an area of seasonal malaria transmission. Parasite Immunol1993;15:513-524.

Riley EM, Allen SJ, Bennett S, Thomas PJ, O’Donnell A, Lindsay SW, et al. Recognition of dominant T cell-stimulating epitopes from the circumsporozoite protein of Plasmodium falciparum and relationship to malaria morbidity in Gambian children. Trans R Soc Trop Med Hyg1990;84:648-657.

Thomson MC, Adiamah JH, Connor SJ, Jawara M, Bennett S, D’Alessandro U, et al. Entomological evaluation of the Gambia’s National Impregnated Bednet Programme. Ann Trop Med Parasitol1995;89:229-241.

Egan AF, Chappel JA, Burghaus PA, Morris JS, McBride JS, Holder AA, et al. Serum antibodies from malaria-exposed people recognize conserved epitopes formed by the two epidermal growth factor motifs of MSP1(19), the carboxy-terminal fragment of the major merozoite surface protein of Plasmodium falciparum. Infect Immun1995;63:456-466.

Quackenbush J. Computational analysis of microarray data. Nat Rev Genet2001;2:418-427.

de Hoon MJ, Imoto S, Nolan J, Miyano S. Open source clustering software. Bioinformatics2004;20:1453-1454.

de Hoon M. Open source clustering software.http://bonsai.ims.u-tokyo.ac.jp/∼mdehoon/software/cluster/index.html (accessed December 2006)..

Java TreeView.http://jtreeview.sourceforge.net/ (accessed December 2006)..

Huson DH. SplitsTree: analyzing and visualizing evolutionary data. Bioinformatics1998;14:68-73.

Taylor RR, Egan A, McGuinness D, Jepson A, Adair R, Drakely C, et al. Selective recognition of malaria antigens by human serum antibodies is not genetically determined but demonstrates some features of clonal imprinting. Int Immunol1996;8:905-915.

Kinyanjui SM, Bull P, Newbold CI, Marsh K. Kinetics of antibody responses to Plasmodium falciparum-infected erythrocyte variant surface antigens. J Infect Dis2003;187:667-674.

Tavazoie S, Hughes JD, Campbell MJ, Cho RJ, Church GM. Systematic determination of genetic network architecture. Nat Genet1999;22:281-285.

Kirkwood BR. Essential Medical Statistics 2nd ed 2003:467pp Blackwell Oxford, United Kingdom. .

Fluck C, Smith T, Beck HP, Irion A, Betuela I, Alpers MP, et al. Strain-specific humoral response to a polymorphic malaria vaccine. Infect Immun2004;72:6300-6305.

Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1–2b trial in Papua New Guinea. J Infect Dis2002;185:820-827.

Thông tin
Thông tin xuất bản

Clinical Chemistry

Tập 53 Số 7

1244-1253

Thông tin tác giả